IHMA Publications & Posters

Poster Presentations by IHMA


  1. 2011 IDSA: Intra-abdominal Pathogens from General Pediatric Wards and Pediatric ICUs: Etiology, ESBL Rate, and Antimicrobial Susceptibility - SMART 2008-2010
  2. 2011 IDSA: Trends in Susceptibility of Tigecycline against Selected Gram-Negative European Pathogens (TEST 2004 – 2010)
  3. 2011 IDSA: Trends in E. coli and K. pneumoniae ESBL Rates in Urinary Tract Infections – TEST 2004-2010
  4. 2011 IDSA: In Vitro Activity of Tigecycline against Commonly-Isolated Pathogens of Skin and Skin Structure Infections in Latin America – TEST 2007-2010
  5. 2011 IDSA: Surveillance Trends in the In Vitro Activity of Tigecycline, TEST 2004 to 2010: A Global Perspective
  6. 2011 IDSA: Variability in Susceptibility of Anaerobes Isolated from Different Body Sites – Results from the Tigecycline European Surveillance Trial, 2009 – 2010
  7. 2011 IDSA: Tigecycline in Vitro Activity against Extended Spectrum Beta-Lactamase Producers in Latin America – TEST 2008-2010
  8. 2011 IDSA: Macrolide Resistance in Streptococcus pneumoniae in the United States and Canada – TEST 2008-2010
  9. 2011 IDSA: In Vitro Evaluation of Tigecycline Against Drug-Resistant Enterococci and Staphylococcus aureus in North America – TEST 2007 - 2010
  10. 2011 IDSA: Cephalosporin Susceptibility Levels of Extended-Spectrum β-Lactamase Genotypes in Latin America
  11. 2011 Vaccine: Distribution of Streptococcus pneumoniae serotypes among global populations
  12. 2011 ICAAC: Activity of Antimicrobial Susceptibility of Escherichia coli from Urinary Tract Infections in North America: SMART 2009-2010
  13. 2011 ICAAC: Activity of Colistin against P. aeruginosa from the TEST Study: The Global Perspective 2009-2010
  14. 2011 ICAAC: Activity of Ertapenem against Gram-Negative Appendicitis Pathogens: SMART 2008-2010
  15. 2011 ICAAC: Activity of Tigecycline and Comparators against Clinical Isolates of Enterobacteriaceae from Medical and Surgical Intensive Care Units in Europe (TEST 2006-2010)
  16. 2011 ICAAC: Comparative Activity of Finafloxacin and Moxifloxacin against Anaerobes
  17. 2011 ICAAC: Comparison of Susceptibility Trends of E. coli from Intra-Abdominal Infections in High-vs. Low-to-Middle-Income Countries: SMART 2005 to the Present
  18. 2011 ICAAC: Distribution of Streptococcus pneumoniae serotypes among populations in Europe
  19. 2011 ICAAC: Effects of Varying MIC parameters on the in vitro Activity of Finafloxacin
  20. 2011 ICAAC: GSK2251052, a Novel Boron-containing Protein Synthesis Inhibitor, with Comparative in vitro Activity against Pseudomonas aeruginosa from a Global Population
  21. 2011 ICAAC: In Vitro Activity of ACHN-490 against Recent Respiratory Tract Pathogens
  22. 2011 ASM: In Vitro Activity of Retapamulin against Staphylococcus aureus and Streptococcus pyogenes Isolated from Skin and Skin Structure Infections
  23. 2011 ASM: Combination of Multiplex PCR with Quellung reaction: a powerful tool for determination of serotypes in Streptococcus pneumoniae
  24. 2011 ASM: Bioburden Levels from Saphenous Vein Grafts Recovered for Transplant: 2007-2010
  25. 2011 ATS: Oral Antibiotic In Vitro Activity in Sinusitis – United States TEST Data 2004-2009
  26. 2011 ATS: Meropenem-resistant Klebsiella pneumoniae in the USA: Data from TEST 2009
  27. 2011 ATS: Monitoring of Tigecycline In Vitro Activity in Nosocomial Pneumonia Isolates from North American Intensive Care Units –TEST Data 2004-2009
  28. 2011 ATS: Trends in Susceptibility of P. aeruginosa to Piperacillin-Tazobactam and Comparators 2004-2009 – Global TEST Analysis
  29. 2011 ATS: Susceptibility of Pathogens Isolated from Community-Acquired Pneumonia (CAP) Sources to Tigecycline (TEST 2004– 2009)
  30. 2011 ATS: Evaluating Multi-Drug Resistant Acinetobacter baumannii in Critical Care Units
  31. 2011 SIS: Incidence of Enterobacter cloacae and E. aerogenes in Intra-abdominal Infections during 2009: Activity of Tigecycline and Comparator Agents (TEST 2009)
  32. 2011 SIS: Activity of Tigecycline and Comparators against North American K. pneumoniae from Gastrointestinal Infections, TEST - 2005-2009
  33. 2011 SIS: Activity of Tigecycline and Comparators Against Clinical Isolates from Medical and Surgical Intensive Care Units (TEST 2009)
  34. 2011 SIS: Susceptibility of Streptococcus agalactiae from Multiple Infection Sites: Results of the Tigecycline Evaluation and Surveillance Trial (TEST) 2009-2010
  35. 2011 SIS: Susceptibility of MRSA from Respiratory and Wound Sources to Linezolid and Comparators in the U.S. from the TEST program – 2004-2010
  36. 2011 SIS: Incidence of Escherichia coli, Extended-spectrum Beta-lactamase Production (ESBL), and the Activity of Tigecycline and Comparators in Intra-abdominal Infections (IAI) in the United States – TEST 2005-2009
  37. 2011 SIS: Trends in Susceptibility of Intra-abdominal Infections in North America – SMART 2005-2010
  38. 2011 ECCMID: Comparative Antibacterial Activity vs. E. coli from Paediatric Patients in North America and Europe: 2006-2009
  39. 2011 ECCMID: Antimicrobial Susceptibility Trends of Enterobacteriaceae from Intra-abdominal Infections in Europe: SMART 2002-2010
  40. 2011 ECCMID: Comparison of Antimicrobial Susceptibility of Escherichia coli from Intra-Abdominal and Urinary Tract Infections in Europe: SMART 2009-2010
  41. 2011 ECCMID: In vitro Activity of Piperacillin-tazobactam and Comparators against P. aeruginosa in Countries of Eastern Europe 2006-2010
  42. 2011 ECCMID: Activity of Colistin Against European P. aeruginosa from the TEST Study: 2009-2010
  43. 2011 ECCMID: Rapid Molecular Detection of Carbapenemase-producers in Enterobacteriaceae Including the Newly Described NDM-1 Carbapenemase (TEST 2009-2010)
  44. 2011 ECCMID: Susceptibility and Incidence of Extended-spectrum Beta-lactamase Producing Escherichia coli and Klebsiella pneumoniae in Intra-abdominal Infections Globally: SMART 2009-2010
  45. 2011 ECCMID: Global Evaluation of Meropenem Non-susceptible Enterobacteriaceae: 2006/2007 versus 2009/2010
  46. 2011 ECCMID: Lack of Ertapenem “MIC Creep” in E. coli: Data from SMART 2002-2010
  47. 2011 ECCMID: Antimicrobial Susceptibility Patterns Associated with European KPC Producers
  48. 2011 ECCMID: In Vitro Activity of Linezolid and Comparators against Enterococcus Phenotypes: Europe 2007-2010
  49. 2011 ECCMID: Analysis of Linezolid In Vitro Activity against Gram-positive Species in Asia - TEST 2004-2010
  50. 2011 ECCMID: Susceptibility of S. aureus from Inpatient vs. Outpatient Settings - a Global Analysis 2009/2010
  51. 2011 ECCMID: Trends in Antimicrobial Susceptibility in European Gram-Positive Anaerobes: The Tigecycline European Surveillance Trial, 2007-2010
  52. 2011 ECCMID: Activity of Tigecycline and Five Comparators against Recent Gram-negative Anaerobes in Europe – The Tigecycline European Surveillance Trial
  53. 2011 ECCMID: Macrolide Resistance in European isolates of Streptococcus pneumoniae (SPN) 2009-2010
  54. 2011 ISAAR: In Vitro Activity of Linezolid and Comparators to Enterococcus Phenotypes: Asia 2004-2010
  55. 2011 ISAAR: Activity of Colistin against Asian Pseudomonas aeruginosa from the TEST Study: 2009-2010
  56. 2011 ISAAR: Trends in Antimicrobial Resistance in Acinetobacter spp. from the Asia TEST Program 2004-2010
  57. 2011 ISAAR: Susceptibility of Gram-negative Pathogens from China to Tigecycline and Comparators (TEST 2009 - 2010)
  58. 2011 ISAAR: Activity of Gram-negative Resistant Anaerobes from Europe to Tigecycline and Comparators: TEST Europe 2009-2010
  59. 2011 ISAAR: Activity of Levofloxacin and Comparators Against Enterobacteriaceae Causing Urinary Tract Infections in Asia: 2004-2010
  60. 2011 ISAAR: Activity of tigecycline against H. influenzae: The Asia TEST program
  61. 2011 ISAAR: Susceptibility of P. aeruginosa From Asia During 2009-2010: Data From TEST Including Multi-drug resistant (MDR) Isolates
  62. 2011 ISAAR: Multi-year Analysis of Levofloxacin Resistance in Enterobacteriaceae in Asia: TEST 2004-2010
  63. 2011 ISAAR: Susceptibility of Enterobacteriaceae Intra-abdominal Pathogens: A Global Analysis 2009-2010
  64. 2011 ISAAR: Susceptibility of Meropenem Non-Susceptible Enterobacteriaceae from Asia to Tigecycline and Comparators: TEST 2009-2010
  65. 2011 ISAAR: Acinetobacter baumannii Susceptibility: Global and Regional Analysis from SMART 2002-present
  66. 2011 ISAAR: Trends in Levofloxacin and Ciprofloxacin Resistance Rates in E. coli from Intra-abdominal Infections in Asia/Pacific – SMART 2005 to the Present
  67. 2011 ISAAR: Susceptibility of Clostridium difficile from Europe: 2007-2010
  68. 2011 ISAAR: Frequency of Selected Multi-drug Resistant (MDR) Gram-positive Pathogens from Asia and Susceptibility to Tigecycline: TEST 2009 – 2010
  69. 2011 ISAAR: Susceptibility of pediatric isolates of Escherichia coli and Klebsiella pneumoniae: A global perspective 2004-2010
  70. 2011 ISAAR: Klebsiella pneumoniae from Intra-abdominal Infections in Asia/Pacific in 2009-2010: Susceptibility and Incidence of ESBL Phenotypes
  71. 2011 ISAAR: Macrolide Resistance in S. pneumoniae Isolates from Asia in The TEST Program 2009-2010
  72. 2011 ISAAR: Comparison of United States Regional Rates of Penicillin Non-susceptible S. pneumoniae: TEST 2004-2006 versus 2008-2010
  73. 2011 ISAAR: Antibiotic susceptibility of Streptococcus pneumoniae from Asia: 2008 – 2010
  74. 2011 ISAAR: Susceptibility of multi-drug resistant Staphylococcus aureus: A global perspective from the TEST program 2006-2010
  75. 2010 WPCCID: Antimicrobial Susceptibility of Urinary Tract Infection Pathogens in Asia – SMART 2009
  76. 2010 WPCCID: Activity of Colistin Against Acinetobacter baumannii Including Multi-drug Resistant Isolates 2007 - 2009
  77. 2010 WPCCID: Activity of Linezolid Against Global Isolates of Streptococcus pneumoniae (SPN) Including Resistant Phenotypes
  78. 2010 WPCCID: Activity of Tigecycline and Comparators Against Enterobacteriacae from Lower Respiratory Sources: 2004 – 2009
  79. 2010 WPCCID: Activity of Levofloxacin Against Isolates from Respiratory Tract Sources in 2008
  80. 2010 WPCCID: Analysis of Linezolid In vitro Activity Against Gram-Positive Species in North America – TEST 2004-2009
  81. 2010 WPCCID: Azithromycin, Levofloxacin and Amoxicillin-Clavulanic Acid Resistance Linked to Age Groups – Results of TEST Program, 2004 - 2009
  82. 2010 WPCCID: Cumulative Susceptibility of Staphylococcus aureus (SA) in 7 Global Regions: 2004-2009
  83. 2010 WPCCID: Demographics of Levofloxacin-resistant Pathogens: Data from T.E.S.T. 2004-2009
  84. 2010 WPCCID: Evaluation of Piperacillin/tazobactam from 2004-2009 in Asia and the Pacific Rim
  85. 2010 WPCCID: Impact of Lowered CLSI Breakpoints on Reported Susceptibility Levels of Imipenem and Meropenem in the TEST Program
  86. 2010 WPCCID: In vitro Activity of Linezolid Against Staphylococcus aureus (SA) with Reduced Vancomycin Susceptibility in North America 2008-2009
  87. 2010 WPCCID: In vitro Activity of Linezolid Against Staphylococcus aureus with Reduced Vancomycin Susceptibility
  88. 2010 WPCCID: In Vitro Activity of Tigecycline Against Streptococcus pneumoniae and Haemophilus influenzae isolates from the Global TEST Program (2004 - 2009)
  89. 2010 WPCCID: In vitro Susceptibility of Acinetobacter baumannii in North America and Europe: Are There Patient Age Related Differences?
  90. 2010 WPCCID: In vitro Susceptibility of Lower Respiratory Tract Isolates of Staphylococcus aureus: a 59 Country Perspective
  91. 2010 WPCCID: In vitro Susceptibility of Staphylococcus aureus (SA) from Elderly Patients: Europe (EU) and North America (NA)
  92. 2010 WPCCID: In vitro Susceptibility of Staphylococcus aureus from Intensive Care Unit Patients: A Global Perspective 2009
  93. 2010 WPCCID: Levofloxacin Susceptibility in Escherichia coli (EC): Asia 2005-2009
  94. 2010 WPCCID: Macrolide Resistance Rates of Streptococcus pneumoniae in Asia – Results of the TEST Study (2004 – 2009)
  95. 2010 WPCCID: Monitoring the Activity of Linezolid Against North American Staphylococcus aureus and Streptococcus pneumoniae from Respiratory Tract Sources: Data from T.E.S.T 2004 - 2009
  96. 2010 WPCCID: Piperacillin/tazobactam In vitro Activity vs. H. influenzae Isolates in Latin America from the TEST Program (2004-2009)
  97. 2010 WPCCID: Pseudomonas aeruginosa in Pediatric Pneumonia: Activity of Piperacillin-Tazobactam and Comparators: 2004-2009
  98. 2010 WPCCID: Susceptibility of Enterococcus Species Including Vancomycin Resistant Phenotypes: A Global Analysis 2004-2009
  99. 2010 WPCCID: Susceptibility of Intra-abdominal Pathogens in Asia – SMART 2009
  100. 2010 WPCCID: Susceptibility Profiles of Staphylococcus aureus Isolated from Skin/Skin Structure Infections 2004-2009
  101. 2010 IDSA: Carbapenem Resistant Respiratory Tract Isolates of Pseudomonas aeruginosa in the United States: Comparative Antibacterial Activity 2007-2009
  102. 2010 IDSA: Fluoroquinolone Resistant Escherichia coli: North America vs. Europe. Comparative Antibacterial Activity 2005-2009
  103. 2010 IDSA: Monitoring “MIC creep” of Linezolid in Staphylococcus aureus: Global data from T.E.S.T 2004 – 2009
  104. 2010 IDSA: In Vitro Activity of Linezolid and Other Antimicrobial Agents Recommended in Treatment of Methicillin-Resistant Staphylococcus aureus from Skin and Soft-Tissue Infections (SSTI) – TEST 2004-2009
  105. 2010 IDSA: In vitro Activity of Linezolid and Comparators Against Non-Tuberculous Mycobacteria
  106. 2010 IDSA: Increasing ermB Phenotype in Macrolide Resistant Streptococcus pneumoniae in the United States: The Tigecycline Evaluation and Surveillance Trial 2004 - 2009
  107. 2010 IDSA: Trends of the Activity of Tigecycline Against Global Clinical Isolates of Enterobacter aerogenes: Data from T.E.S.T 2004 – 2009
  108. 2010 IDSA: In vitro Activity of Tigecycline and Comparators Against Multidrug Resistant Acinetobacter Species: A Global Comparison 2004 - 2009
  109. 2010 IDSA: In Vitro Activity of Tigecycline against Commonly-Isolated Pathogens of Complicated Skin and Soft-Tissue Infections (cSSTIs) – TEST 2004-2009
  110. 2010 IDSA: In vitro activity of Tigecycline and selected comparators against intra-abdominal pathogens – TEST 2008-2009
  111. 2010 IDSA: In Vitro Activity of Tigecycline in Latin America from 2005-2009: Trend Analysis
  112. 2010 IDSA: A Multi-Center, Multi-Country Surveillance Program Identifying Antimicrobial Resistance to ESBL Producing Enterobacteriaceae, VRE and MRSA worldwide, 2008 – 2009
  113. 2010 IDSA: Susceptibility of Enterococcus species including Vancomycin-resistant phenotypes: A European perspective 2004-2009
  114. 2010 IDSA: Does the Antimicrobial Susceptibility of Escherichia coli (EC) Vary by Infection Site? A TEST global analysis: 2008
  115. 2010 IDSA: Increasing Frequency of Vancomycin-Intermediate Staphylococcus aureus: Data from T.E.S.T 2004 – 2009
  116. 2010 IDSA: Global Regional Trends in Penicillin Susceptibility of Streptococcus pneumoniae from the T.E.S.T. study, 2004 - 2009
  117. 2010 IDSA: Persistently High Macrolide Resistance Rates of Streptococcus pneumoniae in Asia – Results of the TEST study (2004 – 2009)
  118. 2010 IDSA: Antimicrobial Susceptibility and ESBL Rates of Escherichia coli from Urinary Tract Infections in SMART 2009
  119. 2010 IDSA: Activity of Antimicrobial Agents Recommended by IDSA/SIS for Empiric Therapy of Complicated Intra-abdominal Infections
  120. 2010 ICAAC: In Vitro Activities of AN3365: A Novel Boron Containing Protein Synthesis Inhibitor, and Other Antimicrobial Agents against Anaerobes and Neisseria gonorrhoeae.
  121. 2010 ICAAC: DNA Micro-Array Test combined with PCR-sequencing: A useful Tool for Rapid Identification of ESBL Genes
  122. 2010 ICAAC: Persistently low levels of levofloxacin resistance in pneumococci
  123. 2010 ICAAC: Changes in Susceptibility of Klebsiella pneumoniae to Ertapenem Over Eight Years: SMART 2002 - 2009
  124. 2010 ICAAC: Lack of Ertapenem “MIC Creep” in Enterobacter cloacae: Data from SMART 2002-2009
  125. 2010 ICAAC: In vitro Activity of GSK1322322, a Novel Peptide Deformylase Inhibitor, against 4,836 Pathogens from Skin and Soft Tissue Infections and Respiratory Tract Infections
  126. 2010 ICAAC: In vitro activity of Linezolid and comparators against Staphylococcus aureus (SA) isolated from nursing home patients
  127. 2010 ICAAC: Activity of Linezolid and comparators to global isolates of Staphylococcus aureus
  128. 2010 ICAAC: Pediatric methicillin resistant Staphylococcus aureus (MRSA) antimicrobial susceptibility: a global analysis 2004-2009
  129. 2010 ICAAC: Susceptibility of Streptococcus agalactiae (GBS): A 59 country analysis 2004 to 2009
  130. 2010 ICAAC: A Global Analysis of Linezolid In Vitro Activity Against Gram-Positive Species – TEST 2004-2008
  131. 2010 ICAAC: Linezolid in vitro Activity Against Gram-Positive Species from Pediatric Respiratory Sources in North America – TEST 2007-2009
  132. 2010 ICAAC: In vitro Spectrum and Potency of Piperacillin/tazobactam Against Pseudomonas aeruginosa North America – the TEST study (2004-2009)
  133. 2010 ICAAC: Susceptibility of bacteremic and respiratory isolates of Acinetobacter baumannii(Ab)
  134. 2010 ICAAC: In vitro susceptibility of Serratia marcescens: North America and Europe
  135. 2010 ICAAC: Antimicrobial susceptibility of selected Enterobacteriaceae causing urinary tract infections (UTI): A global analysis 2004- 2009
  136. 2010 ICAAC: In vitro Activity of Piperacillin/tazobactam in the Asia/Pacific Region: TEST 2004-2009
  137. 2010 ICAAC: Variability in Susceptibility of Anaerobes Isolated From Different Body Sites – Results from the Tigecycline European Surveillance Trial 2007 - 2008
  138. 2010 ICAAC: Impact of NXL104 on Ceftaroline MICs for Bacteria Producing Extended-Spectrum, AmpC, or KPC β-Lactamases
  139. 2010 ICAAC: Activity of Tigecycline and Comparators Against Macrolide Resistant Streptococcus pneumoniae Mediated by mef and erm
  140. 2010 ICAAC: In Vitro Antibacterial Activity Against Selected Species of Glucose non- fermenting Gram-negative Rods in the United States from 2008-2009 - Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  141. 2010 ICAAC: Antimicrobial Susceptibility of E. coli from Intra-Abdominal Infections in Latin America - SMART 2009
  142. 2010 ICAAC: Proposed Revised Disk Diffusion Quality Control Ranges for Doripenem Versus Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853
  143. 2010 ICAAC: Antimicrobial Susceptibility of E. coli from Intra-Abdominal Infections in North America - SMART 2009
  144. 2010 ICEID: Prevalence and Molecular Characterization of Extended Spectrum Beta-lactamase Producing Enterobacteriaceae in Community-Acquired Intra-abdominal Infections – SMART 2002-2009
  145. 2010 ASM: A Comparison of Agar Dilution Testing and Etest Strips for Anaerobes
  146. 2010 ASM: Impact of Haemophilus Test Medium from Different Manufacturers on Tigecycline MICs
  147. 2010 ASM: A Novel DNA Microarray Method for Rapid Detection and Identification of Extended-spectrum β-lactamases (ESBLs) and KPC in Enterobacteriaceae
  148. 2010 ASM: Bioburden Levels from Saphenous Vein Grafts Recovered for Transplant
  149. 2010 ASM: A useful tool in determination of serotypes among Streptococcus pneumoniae: Multiplex-PCR combined with Quellung reaction
  150. 2010 SIS: Comparison of Antimicrobial Susceptibility and Incidence of Extended-Spectrum Beta-Lactamase-Producing Isolates in Medical Intensive Care Units versus Surgical Intensive Care Units – Results from SMART 2008-2009
  151. 2010 ECCMID: Susceptibility of Bacteremic Pseudomonas aeruginosa: A 59 contry analysis from 2004 to 2009
  152. 2010 ECCMID: Comparison of Ceftriaxone Susceptibility Rates of Enterobacteriaceae in the T.E.S.T. Program Using EUCAST vs. 2009 and 2010 CLSI Breakpoints
  153. 2010 ECCMID: Real-Time PCR Analyses of ramA Expression in Tigecycline Non-Susceptible Isolates
  154. 2010 ECCMID: Activity of Piperacillin/tazobactam and comparators against Pseudomonas aeruginosa and Acinetobacter baumannii from South Africa 2004-2009
  155. 2010 ECCMID: In vitro susceptibility of Streptococcus agalactiae: Results of the Tigecycline Evaluation Surveillance Trial (TEST) 2004-2009
  156. 2010 ECCMID: Surveillance of Macrolide Activity against Streptococcus pneumoniae in a Multi-Country Analysis – TEST 2007-2009
  157. 2010 ECCMID: Worldwide Prevalence of Macrolide Resistance Genotypes among Streptococcus pneumoniae from 2004 to 2008
  158. 2010 ECCMID: Macrolide Resistance Mechanisms in Serotypes of Streptococcus pneumoniae
  159. 2010 ECCMID: Gram-Negative Anaerobe Susceptibility Rates in Six European Countries from 2007-2009
  160. 2010 ECCMID: Three Year Susceptibility Analysis of Gram-Positive Anaerobes in Europe – T.E.S.T. 2007-2009
  161. 2010 ECCMID: Activity of Colistin Against Klebsiella pneumoniae from 2007 – 2009, Including Isolates Resistant to Carbapenems
  162. 2010 ECCMID: Global Surveillance Update of Enterobacteriaceae from the T.E.S.T. Program: 2004-2009
  163. 2010 ECCMID: Activity of Colistin Against Enterobacteriaceae from 2007 – 2009, Including Drug-resistant Isolates
  164. 2010 ECCMID: Activity of Tigecycline Against Levofloxacin-Resistant Pathogens from 2008
  165. 2010 ECCMID: Determination of Serotypes Distribution among Streptococcus pneumoniae in North America by Multiplex PCR
  166. 2010 ECCMID: Invasive Streptococcus pneumoniae Serotypes Associated with Adult and Pediatric Isolates from the United States
  167. 2010 ECCMID: Susceptibility of Gram-negative Pathogens Isolated from Intra-abdominal Infections in Europe in 2008-2009 – The SMART Study
  168. 2010 ECCMID: Comparison of Antimicrobial Susceptibility of Gram-negative Pathogens from ICU vs. non-ICU – SMART 2008-2009
  169. 2010 ICID: In vitro Activity of Tigecycline Against Molecularly Defined Carbapenemase Producing Acinetobacter baumannii
  170. 2010 ICID: A Worldwide Surveillance Program Studying the In Vitro Activity of Tigecycline and 10 Common Therapeutic Agents Against Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus species from 2004-2009
  171. 2010 ICID: Invasive Streptococcus pneumoniae Serotypes Associated with In-patient and Out-patient Isolates from the United States
  172. 2009 IDSA: Activity of Antimicrobial Agents Recommended for Empiric Therapy of Complicated Intra-abdominal Infections in North America 2007-2008.
  173. 2009 IDSA: Validity of CLSI Disk Diffusion Zone Correlates for Enterobacteriaceae versus Older Cephalosporins.
  174. 2009 IDSA: Worldwide Monitoring of Multi-Drug Resistant Clostridia (2007 – 2008): Susceptibility to Tigecycline.
  175. 2009 IDSA: Activity of Tigecycline Against Minocycline Resistance Pathogens: A Global Perspective.
  176. 2009 IDSA: In Vitro Activity of Tigecycline Against Staphylococcus aureus with Reduced Susceptibility to Vancomycin. A Global Analysis 2004-2009.
  177. 2009 IDSA: Bacteremic Fluoroquinolone Resistant Pseudomonas aeruginosa A Global in vitro comparative analysis 2004-2008.
  178. 2009 IDSA: Antibiotic Profile of 55 Carbapenem-Resistant Serratia marcescens (CRSm) – T.E.S.T. Program.
  179. 2009 IDSA: Antibiotic Profiles Against Bacteroides fragilis with Reduced Carbapenem Susceptibility – Findings of the T.E.S.T. Program.
  180. 2009 ICAAC: Susceptibility Rates of Anaerobic Bacteria in Six European Nations in 2007-2008
  181. 2009 ICAAC: Multi-Drug Resistant (MDR) Methicillin-Resistant Staphylococcus aureus Isolates in the U.S.
  182. 2009 ICAAC: Temporal Analysis of Tigecycline in South and Central America from 2004-2008
  183. 2009 ICAAC: Pseudomonas aeruginosa and Acinetobacter Isolates from Latin American Hospitals The Activity of Tigecycline and Comparators in the T.E.S.T. Program 2004 - 2008
  184. 2009 ICAAC: Antimicrobial Activity of Tigecycline against Vancomycin-Resistant Enterococcus spp. - A Global Study 2004-2009
  185. 2009 ICAAC: Consistency of Activity of Tigecycline and Comparators vs. Gram-Positive Bacteria in Europe from 2004-2008
  186. 2009 ICAAC: Changes in Susceptibility of Select Non-Fermenters in Europe: 2004-2008
  187. 2009 ICAAC: In vitro Activity of Tigecycline and Comparators vs. ESBL-producing Enterobacteriaceae Globally 2004-2008 - Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
  188. 2009 ICAAC: Trends in Prevalence of ESBL+ E. coli, K. pneumoniae, and K. oxytoca in the Asia/Pacific Rim TEST Program from 2004-2008
  189. 2009 ICAAC: Trends in Tigecycline Activity against Global Respiratory Pathogens from the T.E.S.T. study, 2004 - 2008
  190. 2009 ICAAC: Comparison of Tigecycline with most Commonly-Used Antimicrobials Against Isolates Collected in Spain and Portugal including MRSA between 2004-2009
  191. 2009 ICAAC: In Vitro Activity of Tigecycline Against Recent South African Isolates from Multiple Body Sites During 2008 – 2009
  192. 2009 ICAAC: Activity of Tigecycline Against Streptococcus pneumoniae, an Important Causative Pathogen of Community Acquired Pneumonia (CAP)
  193. 2009 ICAAC: Evaluation of EUCAST and CLSI Cephalosporin Breakpoints vs. ESBL+ and ESBLE. coli, K. pneumoniae, and K. oxytoca in the SMART Study
  194. 2009 ICAAC: Global Susceptibility Patterns of E. coli from Intra-Abdominal Infections to Ertapenem and Comparators – SMART 2008
  195. 2009 ECCMID: A Multicenter Evaluation of In Vitro Activity of Oritavancin and Comparators Against Staphylococci, Enterococci and Streptococci – The ORION Study
  196. 2009 ECCMID: Trends in Susceptibility of Gram-negative Pathogens Isolated from Intra-abdominal Infections in Europe from 2003 to 2007 – The SMART Study
  197. 2009 ECCMID: Impact of Different EUCAST and CLSI Interpretive Breakpoints on Antimicrobial Susceptibility of Pseudomonas aeruginosa – SMART 2007
  198. 2009 ECCMID: Trends in Susceptibility of Gram-negative Pathogens Isolated from Intra-abdominal Infections in North America from 2003 to 2007 – The SMART Study
  199. 2009 ECCMID: An Update to a Comparison of Etest and Agar Dilution MICs for European Anaerobes – A Multi-year Analysis
  200. 2009 ECCMID: In Vitro Activity of Tigecycline Against Pathogens Isolated from Most Common Body Sites – Eastern European Data T.E.S.T. Program 2008
  201. 2009 ECCMID: Regional Variations in Penicillin Resistant Rates Against Streptococcus pneumoniae: The United States 2008
  202. 2009 ECCMID: In Vitro Activity of Tigecycline Against In-patient and Out-patient Pathogens from Centers in Pacific Rim Countries – A Multi-year Update
  203. 2009 ECCMID: Evaluation of In Vitro Activity of Tigecycline and Ten Comparators Against Methicillin-Resistant Staphylococcus Aureus from Europe: TEST Program 2004 - 2008
  204. 2009 ECCMID: Tigecycline In Vitro Activity Against Isolates of S. pneumoniae and H. influenzae: A Multi-year Update from the TEST Program in 2008
  205. 2009 ECCMID: A Comprehensive Analysis of European Data from Tigecycline Evaluation Surveillance Trials (TEST) Program, 2004 – 2008
  206. 2009 ECCMID: Susceptibility of Gram-negative/positive Pathogens Isolated in the United Kingdom and Ireland: A Multi-year Update
  207. 2009 ECCMID: In Vitro Activity of Tigecycline and Comparators Against Nosocomial Pathogens in Italy from 2004-2008
  208. 2009 ECCMID: A Multi-year Update of In Vitro Activity of Tigecycline and Commonly Used Antimicrobials Against Significant Clinical Isolates Collected from 2004 to 2008 in Belgium
  209. 2009 ECCMID: The Tigecycline Evaluation Surveillance Trial (TEST) in Canada from 2004-2008
  210. 2009 ECCMID: Antimicrobial Susceptibility of Bacteremia Pathogens in Europe (2004-2008): Results of the Tigecycline Evaluation Trial (TEST)
  211. 2009 ECCMID: Tigecycline activity against macrolide resistance in Streptococcus pneumoniae mediated by mefE and ermB determinants: A Global Analysis 2008
  212. 2009 ECCMID: Macrolide Resistance in Streptococcus Pneumoniae from the T.E.S.T. Program in Europe: A Multi-year Analysis
  213. 2009 ECCMID: Macrolide Resistance in Streptococcus pneumoniae in the United States and Canada 2004 - 2008
  214. 2009 ECCMID: Changes in Susceptibility of Select Non-Fermenters in Europe: 2004-2008
  215. 2009 ECCMID: Is the Number of ESBLs Increasing in Asia/Pacific Rim Countries? A Longitudinal Evaluation of Organisms Associated with ESBL Production between 2004-2008
  216. 2009 ECCMID: Activity of Tigecycline and Five Comparators Against Recent Gram-positive Anaerobes in Europe – The Tigecycline European Surveillance Trial
  217. 2009 ECCMID: Activity of Tigecycline Against Multi-Drug Resistant Anaerobic Isolates From Europe in 2008 – the T.E.S.T. Program
  218. 2009 ECCMID: Activity of Tigecycline Against Recent European Clinical Isolates of Clostridium difficile
  219. 2009 ECCMID: Emergence of Klebsiella pneumoniae Isolates Possessing KPC ฿-lactamase in Israel, Puerto Rico, Colombia and Greece
  220. 2009 ECCMID: Detection of KPC Enzymes in Klebsiella pneumoniae Isolates from NY/NJ Sites in the TEST Program
  221. 2009 ISAAR: The In Vitro Activity of Tigecycline Against Resistant Enterobacteriaceae Worldwide
  222. 2009 ISAAR: The Activity of Tigecycline Against Minocycline Resistance Pathogens: A Global Perspective
  223. 2009 ISAAR: Evaluation of the Activity of Tigecycline Against Worldwide Levofloxacin-Resistant Pathogens
  224. 2009 ISAAR: The in vitro Potency of Tigecycline and Comparators Against Multidrug Resistant (MDR) Isolates: A Canadian Perspective
  225. 2009 ISAAR: An Age Analysis of the Susceptibility of Gram-positive and Gram-negative Pathogens from Centers in the Middle East: The T.E.S.T. Program (2004-2008)
  226. 2009 ISAAR: The Activity of Antimicrobial Agents Against Australian Bacteremia Isolates: The T.E.S.T. Program (2004-2008)
  227. 2009 ISAAR: Vancomycin Resistant Enterococci (VRE) in Central and South America: Antimicrobial Susceptibility
  228. 2009 ISAAR: The Antimicrobial Susceptibility of Multidrug Resistant (MDR) Acinetobacter Isolates from Latin American Countries: The T.E.S.T. Program
  229. 2009 ISAAR: The Activity of Tigecycline and Comparators to Pathogens by Infection Site Collected in the United States (2004-2008)
  230. 2009 ISAAR: Multi-year Analysis of Changes in Susceptibility Patterns for Tigecycline and Comparators in Western Europe from 2004-2008
  231. 2009 ISAAR: A Yearly Analysis of the In Vitro Activity of Tigecycline and Comparators in Asia/Pacific Rim from 2004-2008
  232. 2009 ISAAR: In Vitro Activity of Tigecycline Against Pathogens Isolated from Cerebrospinal Fluid - T.E.S.T. Program 2008
  233. 2009 ISAAR: Antibacterial Activity of Tigecycline Against Global Isolates of H. influenzae and S. pneumoniae (2004-08): T.E.S.T. Program 2008
  234. 2009 ISAAR: In Vitro Activity of Tigecycline and 10 Common Therapeutic Agents Against Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus species – Global Data, 2004 - 2008
  235. 2009 ISAAR: Antimicrobial Susceptibility of Bacteremic Pathogens in Europe: Tigecycline Evaluation Surveillance Trial TEST) - 2004-2008
  236. 2009 ISAAR: Comparison of In Vitro Activity of Tigecycline and Comparators Against Pathogens from Intensive Care Patients in Europe – T.E.S.T. Program 2008
  237. 2009 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) – United States In Vitro Potency Against Selected Species of Enterococcus spp.
  238. 2009 ISAAR: Evaluation of Tigecycline and Comparators Against Multi-Drug Resistant (MDR) Streptococcus pneumoniae in the United States
  239. 2009 ISAAR: The 2008 Australian Tigecycline Evaluation Surveillance Trial (T.E.S.T)
  240. 2009 ISAAR: In vitro activity of Tigecycline and Comparators Against Global Isolates of Multidrug Resistant Acinetobacter Species (2004 - 2008)
  241. 2009 ISAAR: In-patient and Out-patient Enterobacteriaceae Collected from Australia – T.E.S.T. Program 2008
  242. 2009 ISAAR: Comparing Tigecycline and Comparators Against Multi-drug Resistant (MDR) Pathogens in Turkey in 2008
  243. 2009 ISAAR: Tigecycline Activity in Current (2008) Global Population – An Age Analysis: T.E.S.T. Program
  244. 2009 ISAAR: Surveillance Trends in the In Vitro Antibacterial Activity of Tigecycline in the Years 2004 to 2008 - Tigecycline Evaluation Surveillance Trial (T.E.S.T.): A Global Perspective
  245. 2009 ISAAR: In Vitro Activity of Tigecycline Against Pathogens from Switzerland, Sweden, and The Netherlands – T.E.S.T. Program 2008
  246. 2009 ISAAR: In Vitro Activity of Tigecycline Against Pathogens From France – T.E.S.T. Program 2004 – 2008
  247. 2009 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) – In Vitro Antibacterial Activity Against Selected Species of Non-Glucose Fermenting Gram-negative Rods – United States Data, 2004-2008
  248. 2009 ISAAR: In Vitro Potency of Tigecycline Against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from Asia and the Pacific Rim, 2004 - 2008
  249. 2009 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program – An Update on the In Vitro Antibacterial Activity Against Selected Species of Non-glucose Fermenting Gram negative Rods from Asia and the Pacific Rim – 2008
  250. 2009 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Antibacterial Activity Against Enterococcus species from Asia and the Pacific Rim - 2008
  251. 2009 ISAAR: The Activity of Tigecycline and Comparators Against Fastidious Pathogens from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program from Asia and the Pacific Rim
  252. 2008 ICAAC: Oritavancin: Comparative in vitro Activity against Hospital-Acquired Enterococci from Multicenter Surveillance - The ORION Study
  253. 2008 ICAAC: Activity Of Moxifloxacin, Metronidazole And Four Other Antimicrobial Agents Against Gram-Negative And Gram-Positive Anaerobic Pathogens Isolated From Complicated Intra-Abdominal Infections: Data From An Asian Clinical Trial
  254. 2008 ICAAC: Surveillance of Antimicrobial Activity in Acinetobacter species and Pseudomonas aeruginosa in the United States and Canada - T.E.S.T. Program 2004 - 2007
  255. 2008 ICAAC: Dealing with Acinetobacter (ACT) and Pseudomonas (PSU) in Asia/Pacific Rim (APR) Countries: A Longitudinal Evaluation of 694 ACT and 972 PSU Collected Between 2002 - 2007
  256. 2008 ICID: Comparative Evaluation of Tigecycline and other Antimicrobials in the United States Against Multi-drug Resistant (MDR) Staphylococcus aureus
  257. 2008 ICID: The In Vitro Activity of Tigecycline and Antimicrobial Cross-Resistance Against Enterobacteriaceae Worldwide
  258. 2008 ICID: Tigecycline Comparison with Minocycline Resistance Pathogens. A Worldwide Perspective
  259. 2008 ICID: Evaluation of Tigecycline and Other Antimicrobials in Latin America Against Multi-drug Resistant (MDR) Staphylococcus aureus
  260. 2008 ICID: In Vitro Potency of Tigecycline Against Pathogens from Most Common Body Sites: A Study in Asia/Pacific Rim
  261. 2008 ICID: Tigecycline and Comparators Against Extended-Spectrum Beta-Lactamase (ESBL) Isolates Worldwide
  262. 2008 ICID: An Asia/ Pacific Rim Perspective of Enterobacteriaceae Multi-drug Resistant (MDR) Isolates Against Tigecycline
  263. 2008 ICID: A Global Evaluation of Vancomycin Resistant Enterococci (VRE) Against Tigecycline: The T.E.S.T. Program
  264. 2008 ICID: Tigecycline and Comparators Against S. Pneumoniae: A Global Study
  265. 2008 ICID: Multidrug Resistant (MDR) S. aureus Against Tigecycline and Comparators: A Global Evaluation
  266. 2008 ICID: An Evaluation of Tigecycline and Comparators in the Asia/Pacific Rim for Often Difficult to Treat Pathogens
  267. 2008 ICID: Evaluation of Tigecycline in the United States Against Antimicrobial Resistant Acinetobacter
  268. 2008 ICID: Evaluation of Multidrug Resistant (MDR) Isolates Against Tigecycline: A Canadian Perspective
  269. 2008 ICID: Bacterial Resistance Patterns of Isolates from Various Body Sites: The European T.E.S.T. Program
  270. 2008 ICID: Evaluation of 11 Antimicrobial Agents Against Australian Bacteremia Isolates: The T.E.S.T. Program
  271. 2008 ICID: Efficacy of Tigecycline Against Worldwide Levofloxacin-Resistant Pathogens
  272. 2008 ECCMID: In Vitro Activity of Tigecycline and 13 Comparators against Pathogens from a Global Population of Intensive Care Patients in 2007
  273. 2008 ECCMID: In Vitro Activity of Tigecycline Against In-patient and Out-Patient Isolates from a European Population
  274. 2008 ECCMID: Comparative Analysis of Tigecycline in South America from 2004-2007
  275. 2008 ECCMID: A Global Perspective of Antimicrobial In Vitro Activity from the T.E.S.T. Program: Annual Analysis from 2004-2007
  276. 2008 ECCMID: Tigecycline Activity in Europe: A Comparative Analysis by Country 2007
  277. 2008 ECCMID: Global Trends of Penicillin Resistance Rates in Streptococcus pneumoniae, 2004-2007
  278. 2008 ECCMID: Comparison of Antimicrobial Susceptibilities of Bacteria Isolated in Canada, the United States, and Mexico - Results from the T.E.S.T. Program 2004-2007
  279. 2008 ECCMID: The Efficacy of Tigecycline Against AmpC Producing Enterobacter spp. and Serratia marcescens
  280. 2008 ECCMID: In Vitro Evaluation of Tigecycline Against Drug Resistant Enterococci and S. aureus in the United States
  281. 2007 IDSA: A Global Evaluation of Methicillin-Resistant Staphylococcus aureus from the T.E.S.T. Program
  282. 2007 IDSA: Changes in United States Regional Variations in Penicillin Resistant Rates Against Streptococcus pneumoniae, 1999 to 2006
  283. 2007 ICAAC: Changes of Susceptibility Patterns for Tigecycline and Comparators in Western Europe from 2004-2006
  284. 2007 ICAAC: Determining In Vitro Activity of 14 Antimicrobials in Asia/Pacific Rim from 2004-2006
  285. 2007 ICAAC: Evaluating Multidrug Resistant (MDR) Acinetobacter Isolates from Latin American Countries: The T.E.S.T. Program
  286. 2007 ICAAC: A Comparative Study of 14 Antimicrobials Against Vancomycin Resistant Enterococci (VRE) in Central and South America
  287. 2007 ICAAC: An Age Analysis of Gram-positive and Gram-negative Isolates from Centers in the Middle East: The T.E.S.T. Program
  288. 2007 ICAAC: The Activity of Tigecycline and Comparators to Pathogens by Body Sites Collected in the U.S. (2004-2007)
  289. 2007 ICAAC: A Comparison of the Efficacy of Tigecycline from University Hospitals in Europe and the United States
  290. 2007 ICAAC: Susceptibility Patterns of Tigecycline and Comparators in Latin America from Hospitals of Various Bed Sizes
  291. 2007 ICAAC: The carbapenem PZ-601 (SMP-601) has potent in vitro Gram-positive, Gram-negative and anaerobic bacterial activity.
  292. 2007 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - United States In Vitro Antibacterial Activity Against Selected Species of Enterococcus spp.
  293. 2007 ECCMID: Comparison of In Vitro Activity of Tigecycline against Pathogens from Intensive Care Patients in Europe - T.E.S.T. Program 2006
  294. 2007 ECCMID: In Vitro Activity of Tigecycline Against Pathogens Isolated from Cerebrospinal Fluid - T.E.S.T. Program 2006
  295. 2007 ECCMID: Antimicrobial Susceptibility of 2,537 Bacteremia Causative Pathogens: Tigecycline Evaluation Surveillance Trial (TEST) in Europe 2004-2006
  296. 2007 ECCMID: Tigecycline In Vitro Activity Against Often Difficult to Treat European Pathogens
  297. 2007 ECCMID: Antibacterial Activity of Tigecycline Against H. influenzae and S. pneumoniae (2004-06) Global Population - T.E.S.T. Program 2006
  298. 2007 ECCMID: Variable Resistance Patterns among Tigecycline and 10 Comparators against Multi-Drug Resistant Acinetobacter from the T.E.S.T. Program
  299. 2007 ECCMID: In Vitro Activity of Tigecycline and 10 Common Therapeutic Agents Against Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus species - Global Data, 2004 - 2006
  300. 2007 ECCMID: Evaluation of In Vitro Activity of Tigecycline and Ten Comparators Against Methicillin-Resistant Staphylococcus aureus from 38 Countries: TEST Program 2004 - 2006
  301. 2007 ECCMID: Patterns of Susceptibility of Gram-negatives/positives Isolated in the United Kingdom and Ireland
  302. 2007 ECCMID: Changes in United States Regional Variations in Penicillin Resistant Rates of Streptococcus pneumoniae, 1999 to 2006
  303. 2007 ECCMID: Impact of Different FDA and EU Breakpoints on Bacterial Susceptibility Patterns - Analysis of Data from the T.E.S.T Program
  304. 2007 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - United States In Vitro Antibacterial Activity Against Selected Species of Glucose Non-fermenting Organisms
  305. 2007 ISAAR: Susceptibilities of Hospital- and Community-Acquired Clinical Pathogens from Asian Hospitals: TEST Program in Asia 2006
  306. 2007 ISAAR: Activity of Tigecycline Against Antibiotic Resistant Clinical Isolates of Enterobacteriaceae from the United States - The T.E.S.T. Program
  307. 2007 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program -In Vitro Antibacterial Activity Against Selected Gram-Negative Clinical Pathogens from Asia and the Pacific Rim
  308. 2007 ISAAR: Antimicrobial Susceptibility of 2,537 Bacteremia Causative Pathogens: Tigecycline Evaluation Surveillance Trial (TEST) in Europe 2004-2006
  309. 2007 ISAAR: In Vitro Antibacterial Activity of Tigecycline Against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) in the USA
  310. 2007 ISAAR: Evaluating Multi-Drug Resistant Acinetobacter in a Worldwide Study
  311. 2007 ISAAR: Variability of Antimicrobial Susceptibility in Isolates from Patients in Different Age Groups in the USA: 2004-2006
  312. 2007 ISAAR: Antimicrobial Activity of Tigecycline and Comparators from Inpatient and Outpatient Pathogens in North America
  313. 2007 ISAAR: Antimicrobial Susceptibility of Isolates Collected from Different Body Sites in Asia and the Pacific Rim: Tigecycline Evaluation Surveillance Trial (TEST)
  314. 2007 ISAAR: In Vitro Activity of Tigecycline Against In-patient and Out-patient Enterobacteriaceae Collected From Australia - T.E.S.T. Program 2006
  315. 2007 ISAAR: Tigecycline and Comparator Agents In Vitro Activity Against Recently Collected Extended Spectrum Beta-Lactamase Isolates - TEST Program
  316. 2007 ISAAR: Antibiotic Activity against Vancomycin Resistant Enterococci from the Tigecycline Evaluation Surveillance Trials (TEST) Program 2006
  317. 2007 ISAAR: In Vitro Activity of Tigecycline and 10 Common Therapeutic Agents Against Current Isolates of Staphylococcus aureus and Enterococcus Species Resistant to Other Drugs - Worldwide Data, 2006
  318. 2007 ISAAR: Tigecycline and Comparators Susceptibility Against Enterobacteriaceae of Various Resistant Phenotypes Globally
  319. 2007 ISAAR: Comparison of Antimicrobial Susceptibility of Isolates from Various Body Sites: Western European Results from Tigecycline Evaluation Surveillance Trial (TEST) 2004-2006
  320. 2007 ISAAR: Out-patient vs. In-patient Isolates from an Eastern European Population: 2004-2006 T.E.S.T.
  321. 2007 ISAAR: Global Study to Determine Antibacterial Activity of Tigecycline and Comparators Against H. influenzae and S. pneumoniae from 2004-2006
  322. 2007 ISAAR: In Vitro Activity of Tigecycline and Comparators Against Difficult-to-Treat European Isolates
  323. 2007 ISAAR: Surveillance Trends in the In Vitro Antibacterial Activity of Tigecycline in the years 2004 to 2006 -Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  324. 2007 ICMS: A Presentation of Global Data from Tigecycline Evaluation Surveillance Trials (TEST) Program, 2004 - 2006
  325. 2007 ICMS: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Australian Experience, 2006
  326. 2007 ICMS: The In-Vitro Antibacterial Activity of Tigecycline from an Asia/Pacific Rim Population - The T.E.S.T. Program 2006
  327. 2006 WestPac: Patterns of susceptibility of gram negatives/positives isolated in the United Kingdom and Ireland
  328. 2006 WestPac: In vitro Activity of Tigecycline and Comparators in Belgium from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
  329. 2006 WestPac: In Vitro Activity of Tigecycline and Comparators Against Pathogens from Switzerland, Sweden and The Netherlands
  330. 2006 WestPac: In Vitro Activity of Tigecycline against In-patient and Out-patient Pathogens Collected From Centers in Pacific Rim Countries - T.E.S.T. Program 2006
  331. 2006 WestPac: In Vitro Activity of Tigecycline Against South African Blood, Respiratory Tract, and Urinary Tract Isolates - T.E.S.T. Program 2006
  332. 2006 WestPac: In Vitro Activity of Tigecycline Against Pathogens Isolated from Most Common Body Sites - Eastern European Data - T.E.S.T. Program 2006
  333. 2006 WestPac: Comparison of Antimicrobial Susceptibility of 1,267 Isolates from Various Body Sites: South American Results from Tigecycline Evaluation Surveillance Trial (TEST) 2004-2006
  334. 2006 WestPac: Tigecycline’s In Vitro Activity vs. Isolates from Intensive Care and Non-Intensive Care Patients - Western Europe T.E.S.T. Program 2006
  335. 2006 WestPac: North American inpatient and outpatient pathogens: Monitoring resistance in the TEST study
  336. 2006 WestPac: Susceptibilities of hospital- and community-acquired pathogens in Asia in 2006
  337. 2006 WestPac: Gender Analysis of Global Pathogen Susceptibility (2004-2006): Tigecycline vs. Comparators in the TEST Study
  338. 2006 WestPac: Tigecycline is Active Against Global Isolates of S. pneumoniae and H. influenzae: Results from the TEST Program in 2006
  339. 2006 WestPac: Tigecycline is active against Eastern European in-patient and out-patient clinical isolates
  340. 2006 WestPac: In vitro activity of Tigecycline Against Global Isolates of Multidrug Resistant Acinetobacter Species
  341. 2006 WestPac: Comparison of Antimicrobial Susceptibility of Isolates From Various Body Sites: Asia/Pacific Results From the Tigecycline Evaluation Surveillance Trial (TEST) 2004-2006
  342. 2006 WestPac: Susceptibility to Tigecycline of 23,125 Pathogens Isolated from Common Body Sites and Tissues in North America
  343. 2006 WestPac: Global Evaluation of Tigecycline and Comparators from 2004 to 2006 - Analyzed by Age
  344. 2006 WestPac: Age-Related Variances in Pathogen Susceptibilities in the USA (2004-2006): Results from the TEST Study
  345. 2006 WestPac: Tigecycline Antibacterial Activity in Current (2004-06) Western European Population - An Age Population Analysis - T.E.S.T. Program 2006
  346. 2006 WestPac: Tigecycline In Vitro Activity in Pathogens Collected from France
  347. 2006 WestPac: In Vitro Activity of Tigecycline and Commonly-Used Antimicrobials Against 1,559 Isolates Collected from 2004 to 2006 in Spain and Portugal
  348. 2006 WestPac: Activity of Tigecycline and Comparators in Nosocomial Pathogens from Italy
  349. 2006 WestPac: Bacterial pathogens in hospitalized patients in Germany: Susceptibility patterns from the TEST study
  350. 2006 WestPac: Changes in United States Regional Variations in Penicillin Resistant Rates Against Streptococcus pneumoniae, 1999 to 2006
  351. 2006 WestPac: Antimicrobial Susceptibility Of Nosocomial Pathogens in South America - Results From the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) 2004-2006
  352. 2006 WestPac: In Vitro Evaluation of Tigecycline and Comparators from 2004 to 2006 - A Global Study
  353. 2006 WestPac: Comparison of Antimicrobial Susceptibility of Isolates from Various Body Sites: Western European Results from Tigecycline Evaluation Surveillance Trial (TEST) 2004-2006
  354. 2006 WestPac: In Vitro Activity of Tigecycline Against In-patient and Out-patient Enterobacteriaceae Collected from Australia - T.E.S.T. Program 2006
  355. 2006 WestPac: Evaluation of Tigecycline and Comparators in Nosocomial Pathogens from South America
  356. 2006 WestPac: Tigecycline vs. Comparators Against Multidrug Resistant Pathogens in Turkey in 2006
  357. 2006 IDSA: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Nosocomial Pathogens in South America, 2004-2006
  358. 2006 IDSA: In Vitro Activity of Tigecycline Against 24,278 Pathogens Isolated from Common Body Sites and Tissues in North America
  359. 2006 ICAAC: In Vitro Activity of Tigecycline Against Pathogens From France – T.E.S.T. Program 2006
  360. 2006 ICAAC: Spectrum and potency of tigecycline and comparators against nosocomial pathogens in Italy
  361. 2006 ICAAC: In vitro Activity of Tigecycline and Commonly-Used Antimicrobials Against 549 Isolates Collected From 2004 to 2006 in Belgium
  362. 2006 ICAAC: In Vitro Activity of Tigecycline Against Pathogens From Switzerland, Sweden, and The Netherlands - T.E.S.T. Program 2006
  363. 2006 ICAAC: Surveillance Trends in the In Vitro Antibacterial Activity of Tigecycline in the years 2004 to 2006 - Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  364. 2006 ICAAC: Susceptibility of Tigecycline and Comparators in Nosocomial Pathogens from South America Hospitals: T.E.S.T. program 2004-2006
  365. 2006 ICAAC: Tigecycline Antibacterial Activity in Current (2004-06) Global Population - An Age Population Analysis - T.E.S.T. Program 2006
  366. 2006 ASM: An In Vitro Evaluation of Tigecycline and Ten Comparators against Methicillin-Resistant Staphylococcus Aureus Collected From a Recent Global Population: TEST Program 2006
  367. 2006 ECCMID: Tigecycline In Vitro Activity in an Out-patient vs. In-patient Global Population
  368. 2006 ECCMID: In Vitro Activity of Tigecycline and Comparators against Community and Hospital Acquired Infections In The United States - T.E.S.T. Program 2006
  369. 2006 ECCMID: Tigecycline In Vitro Activity against In-patient and Out-patient Pathogens Collected From Centers In Europe - T.E.S.T. Program 2006
  370. 2006 ECCMID: Asia and Pacific Rim Community vs. Hospital Acquired Infections - In vitro Activity Against Tigecycline and Comparators
  371. 2006 ECCMID: The In Vitro Activity of Tigecycline and 10 Comparators in a Global Population - T.E.S.T. Program 2006
  372. 2006 ECCMID: Tigecycline Antibacterial Activity in Current (2004-06) United States Pathogen Population
  373. 2006 ECCMID: Tigecycline In Vitro Activity in Current European Pathogens - T.E.S.T. Program 2006
  374. 2006 ECCMID: Extended Spectrum Beta-Lactamase Producing Enterobacteriaceae Evaluated In Vitro Against Tigecycline and Comparator Agents - T.E.S.T. Program 2006
  375. 2006 ECCMID: Tigecycline In Vitro Activity Against Often Difficult To Treat Pathogens From Centers In Asia/Pacific Rim - T.E.S.T. Program 2006
  376. 2006 ECCMID: Tigecycline In Vitro Evaluation of 1,145 Methicillin-Resistant Staphylococcus Aureus
  377. 2006 ECCMID: In Vitro Evaluation of Tigecycline Against 288 Recent Isolates of Vancomycin-Resistant Enterococci (VRE) - T.E.S.T. Program 2006
  378. 2006 ECCMID: Tigecycline In Vitro Activity Against Multi-Drug Resistant Acinetobacter spp. In The T.E.S.T. Program Global Data
  379. 2006 ECCMID: Evaluating Tigecycline Against Cross Resistant Enterobacteriaceae in the Global T.E.S.T. Program
  380. 2006 ECCMID: Acinetobacter Resistance In Clinical Isolates from The United States Evaluated against Tigecycline and 10 Comparators
  381. 2006 ECCMID: Cross-Resistance in Clinical Isolates of Enterobacteriaceae from the United States Evaluated against Tigecycline and 10 Comparator Antimicrobial Agents
  382. 2006 ECCMID: Evaluating Cross Resistance for Enterobacteriaceae as Compared to Tigecycline For the T.E.S.T. Program in Europe
  383. 2006 ECCMID: Sampling of Staphylococcus aureus and Enterococcus species Isolates Resistant To Other Drugs Evaluated against Tigecycline- T.E.S.T. Program Global Data
  384. 2006 ECCMID: Tigecycline In Vitro Activity against Staphylococcus aureus and Enterococcus Strains Resistant To Other Drugs In United States, 2004 - 2006
  385. 2006 ECCMID: Antibiotic Cross Resistance for Staphylococcus aureus and Enterococcus spp Among Tigecycline and 10 Comparator
  386. 2006 ECCMID: Multi-Drug Resistant Acinetobacter in the United States Evaluated against Tigecycline - T.E.S.T. Program 2006
  387. 2006 ECCMID: In Vitro Activity of Multi-Drug Resistant Acinetobacter against Tigecycline from the T.E.S.T. Program in Europe
  388. 2006 ECCMID: Determining Tigecycline\'s in vitro Activity Multi-Drug Resistant Enterobacteriaceae from the T.E.S.T. Program - Global Data
  389. 2006 ECCMID: In Vitro Activity Tigecycline and 10 Broad Spectrum Comparators against Multi-Drug Resistant Staphylococcus aureus: A Multi-nation Evaluation
  390. 2006 ICMS: Tigecycline In-Vitro Antibacterial Activity from a Global Perspective - The T.E.S.T.
  391. 2006 ICMS: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity of Tigecycline at Flinders Medical Centre, South Australia
  392. 2006 ICMS: The In-Vitro Antibacterial Activity of Tigecycline from an Asia/Pacific Rim
  393. 2006 ICMS: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Gram-Negative Clinical Pathogens from Asia and the Pacific Rim
  394. 2006 ICMS: Tigecycline in vitro Activity against Gram-Positive Pathogens and Common Resistant Phenotypes from Asia and the Pacific Rim - The T.E.S.T. Program 2005
  395. 2005 ICAAC: Retapamulin (SB-275833), A Novel Topical Pleuromutilin, Is Active Against Community Associated Methicillin and Mupirocin-Resistant S. aureus Isolates From Uncomplicated Skin And Skin Structure Infections (SSSIs)
  396. 2005 ICAAC: Retapamulin (SB-275833), a Novel Pleuromutilin – a Multi-center Global Surveillance of Activity Against 3,797 Beta and Alpha Hemolytic Streptococci Isolated from Skin and Skin Structure Infections (SSSIs)
  397. 2005 ICAAC: In Vitro Activity of Retapamulin (SB-275833), a Novel Topical Antimicrobial, against 3721 Gram-Positive Isolates Associated with Skin and Skin Structure Infections (SSSIs) From 17 Sites in North America
  398. 2005 ICAAC: A Multi-center Global Surveillance Study of the In Vitro Activity of Retapamulin (SB-275833), A Novel Topical Pleuromutilin Against 2950 Clinical Isolates of S. aureus and Coagulase Negative Staphylococci from Uncomplicated Skin and Skin Strucure Infectio
  399. 2005 ICAAC: An In Vitro Evaluation Of Tigecycline In An In-Patient vs. Out-Patient Population Worldwide
  400. 2005 ICAAC: In-Patient vs. Out-Patient In Vitro Evaluation Of Pathogens Collected From Centers In Europe
  401. 2005 ICAAC: The T.E.S.T. Program - Determining The Anti-bacterial Activity of Tigecycline and 10 Comparators in a Global Population
  402. 2005 ICAAC: Tigecycline Antibacterial Activity in Current (2004-05) U.S. Pathogen Population
  403. 2005 ICAAC: T.E.S.T.: Validating the Activity of Tigecycline in Current European Pathogens
  404. 2005 ICAAC: Evaluation of Tigecycline Against Often Difficult to Treat Pathogens From Centers in Asia/Pacific Rim
  405. 2005 ICAAC: Recently Collected Extended Spectrum Beta-Lactamase (ESBL) Isolates (354) Evaluated In Vitro Against Tigecycline and Comparator Agents: Global Perspective
  406. 2005 ICAAC: Methicillin-Resistant Staphylococcus Aureus (1,030) Collected From a Recent Global Population: Tigecycline In Vitro Evaluation
  407. 2005 ICAAC: Vancomycin Resistant Enterococci (VRE) - A Global Problem: Evaluation of Tigecycline Against Recent Isolates From Multi-Centers Globally
  408. 2005 ICAAC: Tigecycline in vitro Activity against a Sampling of Staphylococcus aureus and Enterococcus species Isolates Resistant To Other Drugs in the T.E.S.T. Program Worldwide
  409. 2005 ICAAC: Tigecycline in vitro Activity against Staphylococcus aureus and Enterococcus strains Resistant To Other Drugs In The T.E.S.T. Program - United States, 2004 - 2005
  410. 2005 ICAAC: In vitro Activity of Tigecycline against Multi-Drug Resistant Acinetobacter from the T.E.S.T. Program Worldwide
  411. 2005 ICAAC: Multi Drug Resistant (MDR) S. aureus Are Susceptible to Tigecycline: T.E.S.T Program - United States Surveillance
  412. 2005 ASHP: Acinetobacter Resistance In The United States: In Vitro Evaluation Of Tigecycline and Comparators Against Recent Isolates
  413. 2005 ASHP: Determining Tigecycline in vitro Activity against Multi-Drug Resistant Enterobacteriaceae for the T.E.S.T. Program - United States Data
  414. 2005 ASHP: Evaluating Antibiotic Cross-Resistance in Clinical Isolates of Enterobacteriaceae from the United States against 10 Antimicrobial Agents - The T.E.S.T. Program
  415. 2005 ASHP: In vitro activity of Tigecycline against Multi-Drug Resistant Acinetobacter in the United States - T.E.S.T. Program 2004- 2005
  416. 2005 ASHP: Tigecycline in vitro Activity against Staphylococcus aureus and Enterococcus strains Resistant To Other Drugs In The T.E.S.T. Program - United States, 2004 - 2005
  417. 2005 IDSA: Resistance Patterns of Methicillin- and Mupirocin-resistant S. aureus from Uncomplicated Skin and Skin Structure Infections (SSSIs) in the United States from March 2004–March 2005; Retapamulin Surveillance Study
  418. 2005 IDSA: Gram Positive Isolates Associated with Skin and Skin Structure Infections (SSSIs) and Collected from Sites in the United States are Highly Susceptible to Retapamulin (SB275833), a Novel Topical Antimicrobial
  419. 2005 IDSA: A Global Surveillance Program to Determine the In Vitro Activity of Tigecycline against Multi-Drug Resistant Acinetobacter spp.
  420. 2005 IDSA: A Global Surveillance to Determine Tigecycline’s In Vitro Activity against Multiple Resistant Phenotypes of Enterobacteriaceae
  421. 2005 IDSA: Determining The Anti-bacterial Activity of Tigecycline and 10 Comparators Worldwide
  422. 2005 ACCP: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - United States In Vitro Antibacterial activity Against Selected Species of Glucose Non-fermenting Organisms
  423. 2005 ACCP: United States In Vitro AntibacterialActivity of Tigecycline against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program
  424. 2005 ACCP: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - United States In Vitro Antibacterial Activity against Selected Species of Enterococci
  425. 2005 ACCP: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae in the United States
  426. 2005 ICC: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Gram-positive and Gram-negative Pathogens in Asia and Pacific Rim
  427. 2005 ICC: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 3,935 Gram-positive and Gram-negative Pathogens in Europe
  428. 2005 ICC: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - Global In Vitro Antibacterial Activity against 14,706 Gram-positive and Gram-negative Pathogens
  429. 2005 ICC: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 9,567 Gram-positive and Gram-negative Pathogens in the United States
  430. 2005 ASM: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae in the United States
  431. 2005 ASM: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Selected Species of Enterococcus spp. - North America Data, 2004
  432. 2005 ASM: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against Selected Species of Non-Glucose Fermenting Gram-negative Rods - United States Data, 2004
  433. 2005 ASM: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - Global In Vitro Antibacterial Activity against 14,705 Gram-positive and Gram-negative Pathogens
  434. 2005 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity against Selected Species of non-glucose fermenting Gram negative rods from Asia and the Pacific Rim
  435. 2005 ISAAR: In Vitro Study to Determine the Activity of Tigecycline against Fastidious Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program from Asia and the Pacific Rim
  436. 2005 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity against Selected Enterococcus species from Asia and the Pacific Rim
  437. 2005 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity against Nosocomial and Community Pathogens from Asia and the Pacific Rim
  438. 2005 ISAAR: In Vitro Antibacterial Activity of Tigecycline Against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program from Asia and the Pacific Rim
  439. 2005 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae from the Pacific Rim
  440. 2005 ECCMID: A Comparative In Vitro Analysis of Amoxicillin-clavulanic Acid and Seven Comparative Agents in 15,499 Peadiatric Respiratory Isolates.
  441. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Global In Vitro Antibacterial Activity against Selected Species of Enterobacteriaceae
  442. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae in the United States
  443. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - European In Vitro Antibacterial Activity against Selected Species of Enterococci
  444. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Global In Vitro Antibacterial Activity against Selected Species of Enterococci
  445. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - European In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae
  446. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - United States In Vitro Antibacterial Activity against Selected Species of Enterococci
  447. 2005 ECCMID: Microdilution Testing Methodology for Tigecycline: Addition of A Biocatalytic Oxygen-Reducing Agent May Be Required in The Absence of Fresh Media
  448. 2005 ECCMID: European In Vitro Antibacterial Activity of Tigecycline against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program
  449. 2005 ECCMID: Global In Vitro Antibacterial Activity of Tigecycline against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program
  450. 2005 ECCMID: United States In Vitro Antibacterial Activity of Tigecycline against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program
  451. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - European In Vitro Antibacterial Activity against Selected Species of Glucose Non-fermenting Organisms
  452. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Global In Vitro Antibacterial Activity against Selected Species of Glucose Non-fermenting Organisms
  453. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - United States In Vitro Antibacterial activity Against Selected Species of Glucose Non-fermenting Organisms
  454. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against Gram-positive and Gram-negative Pathogens in Asia
  455. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 3,686 Gram-positive and Gram-negative Pathogens in Europe
  456. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 9,063 Gram-positive and Gram-negative pathogens in the United States
  457. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - Global In Vitro Antibacterial Activity against 13,669 Gram-positive and Gram-negative Pathogens
  458. 2005 SHEA: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae in the United States
  459. 2005 SHEA: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 9,063 Gram-positive and Gram-negative pathogens in the United States
  460. 2005 SHEA: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - United States In Vitro Antibacterial activity Against Selected Species of Glucose Non-fermenting Organisms
  461. 2004 WestPac: In Vitro Study to Determine the Activity of Tigecycline as Compared to Nine Comparator Antimicrobials Against Methicillin Resistant and Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  462. 2004 WestPac: In Vitro Study to Determine the Activity of Tigecycline as Compared to Nine Comparator Antimicrobials Against Vancomycin Resistant and Sensitive Enterococcus faecium Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  463. 2004 WestPac: In Vitro Study to Determine the Activity of Tigecycline as Compared to Nine Comparator Antimicrobials Against Various Species of Enterobacteriaceae from the Tigecycline Evaluation Surveillance Trial (T.E.S.T)
  464. 2004 WestPac: In Vitro Study to Determine the Activity of Tigecycline as Compared to Nine Comparator Antimicrobials Against Various Fastidious Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  465. 2004 ICAAC: The Effects of CO2 on the In Vitro Activity of Telithromycin when Using Etestฎ Compared with Broth Microdilution in 7 Reference Laboratories
  466. 2004 ICAAC: Quinolone resistance in Streptococcus pneumoniae evaluated in three Asian countries during 2003-2004
  467. 2004 ICAAC: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates
  468. 2004 ICAAC: In Vitro Antibacterial Activity of Tigecycline Against Isolates of Vancomycin-Resistant and -Sensitive Enterococcus faecium from the Tigecycline Evaluation Surveillance Trial (TEST)
  469. 2004 ICAAC: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae
  470. 2004 ICAAC: Microdilution Testing Methodology for Tigecycline: Addition of A Biocatalytic Oxygen-Reducing Agent May Be Required in The Absence of Fresh Media
  471. 2004 ICAAC: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In vitro Antibacterial Activity Against Fastidious Isolates
  472. 2004 ASM: Comparison In Vitro Activity of Garenoxacin Against 618 Clinical Aerobes and Anaerobes Isolated from Clinical Gynecological Infections
  473. 2004 ASM: Piperacillin/tazobactam MIC and Disk Correlation Study for ESBL and Non-ESBL Producing Organisms Using NCCLS Published Guidelines versus Proposed Breakpoints
  474. 2004 ICID: Tigecycline In Vitro Antibacterial Activity Against 1,499 Isolates of Enterobacteriaceae
  475. 2004 ICID: Tigecycline In Vitro Antibacterial Activity Against 249 Methicillin Resistant and 250 Methicillin Sensitive Staphylococcus aureus Isolates
  476. 2004 ICID: Tigecycline In Vitro Antibacterial Activity Against Isolates of Non-Enterobacteriaceae
  477. 2003 ICAAC: Comparison InVitro Activity of Garenoxacin (BMS-284756) Against 706 Clinical Aerobes Isolated From Complicated Skin and Skin Structure Infections
  478. 2003 ICAAC: In Vitro Activity of Garenoxacin (BMS-284756) Against 465 of Clinical Anaerobes Isolated From Intra-abdominal Infections
  479. 2003 ICAAC: In Vitro Antibacterial Activity of Tigecycline, a Novel Glycylcycline, Against Clinical Isolates of Enterobacteriaceae
  480. 2003 ICAAC: Tigecycline, a Novel Glycylcycline with Promising Anti-Staphylococcal Activity
  481. 2003 ICAAC: In Vitro Study of Tigecycline Against 776 Clinical Isolates of Non-Enterobacteriaceae From Hospitals Across Europe
  482. 2003 ASM: Global Survey of In Vitro Antimicrobial Susceptibilities of Bacteroides, Prevotella, Fusobacterium, Clostridium, Eubacterium, and Peptostreptococcus Species
  483. 2003 ASM: Comparison of Etest and Agar Dilution for the Susceptibility Testing of 933 Anaerobic Isolates
  484. 2003 ASM: A Multi-National In Vitro Surveillance of ESBL Producers, VREF and MRSA. Results of the Pan-European Antimicrobial Resistance Using Local Surveillance (PEARLS) Study: 2001 – 2002
  485. 2003 ECCMID: Accuracy in determining telithromycin MIC values against Streptococcus pneumoniae: Haemophilus influenzae and Streptococcus pyogenes: Etest vs. Broth Microdilution
  486. 2002 ICAAC: Regional Incidence of Extended Spectrum Beta-Lactamase (ESBL) Producing Enterobacteriaceae, Vancomycin Resistant Enterococcus Faecium (VREF), and Methicillin Resistant Staphylococcus Aureus (MRSA) from 36 Centers in 16 Countries:
  487. 2002 ASM: A Recent Evaluation of In Vitro Activity of Gemifloxacin (GEM), Moxifloxacin (MOX), Gatifloxacin (GAT) and Levofloxacin (LEV) Against 2517 Streptococcus pneumoniae (SP ) Isolates Recovered From Sterile Body Sites: The FACTS Study, 2000–2001
  488. 2002 ASM: Determination of Gemifloxacin (GEM), Moxifloxacin (MOX), Gatifloxacin (GAT) and Levofloxacin (LEV) Resistant Streptococcus pneumoniae (SP ) Isolates from Respiratory and Blood Sources in a Multi-center In Vitro Evaluation: The FACTS Study, 2000–2001
  489. 2002 ASM: Activity of Respiratory Fluoroquinolones Gemifloxacin (GEM), Moxifloxacin (MOX), Gatifloxacin (GAT) and Levofloxacin (LEV) Against 4982 Upper and Lower Respiratory Tract Streptococcus pneumoniae (SP ) Isolates Recovered From 124 Sites in the United States
  490. 2002 ECCMID: A 2001 Multi-Center, Multi-Country Surveillance Study Identifying Antibiotic Resistance To Extended Spectrum Beta-Lactamase Producing Enterobacteriaceae, Vancomycin Resistant Enterococcus Faecium and Methicillin Resistant Staphylococcus Aureus Isolates
  491. 2002 ICID: Incidence Of Extended Spectrum Beta-Lactamase Producing Enterobacteriaceae (ESBL), Vancomycin Resistant Enterococcus Faecium (VREF) And Methicillin Resistant Staphylococcus Aureus (MRSA) In France Through the Pan-European Antimicrobial Resistance Using Lo
  492. 2002 ICID: Checking For Incidence of Extended Spectrum Beta-Lactamase (ESBL) Producing Enterobacteriaceae, Vancomycin Resistant Enterococcus Faecium (VREF) and Methicillin Resistant Staphylococcus Aureus (MRSA) in 26 Centers from 12 European Countries: PEARLS Study
  493. 2002 ICID: Extended Spectrum Beta-Lactamase (ESBL) Producing Enterobacteriaceae, Vancomycin Resistant Enterococcus Faecium (VREF) and Methicillin Resistant Staphylococcus Aureus (MRSA): Pan-European Antimicrobial Resistance Using Local Surveillance (PEARLS) - A 2001
  494. 2001 ASM: In Vitro Activity of Gatifloxacin Against Respiratory Tract Pathogens from Hospitalized Patients Isolated in 108 Sites from the United States
  495. 2001 ASM: Quinolone, Beta-lactam and Macrolide Activity Against S. pneumoniae from Hospitalized Patients in the United States Irrespective of Regional Resistance Patterns
  496. 2001 ASM: Comparative Activity of Gatifloxacin Against P. aeruginosa and Enterobacteriaceae Isolated from Hospitalized Patients in the United States
  497. 2001 ASM: Activity of Gatifloxacin Against Penicillin-, Macrolide- and Ciprofloxacin-Resistant S. pneumoniae Isolated from Pediatric, Adult and Elderly Hospitalized Patients in the United States
  498. 2000 ICAAC: In Vitro Activity of Gemifloxacin Against Multiple-drug-resistant Strains of Streptococcus pneumoniae Isolated From 42 Countries in North America, Latin America, Europe, Asia, South Pacific and Africa/Middle East
  499. 2000 ICAAC: Global Resistance Patterns of Quinolones, Macrolides and b-Lactams From a Multi-center, Multi-country Study of >40,000 Isolates: The Gemifloxacin Surveillance Study
  500. 2000 ICAAC: Gemifloxacin Comparative In Vitro Surveillance Study of Penicillin- and Macrolide-resistant Pneumococci and other Respiratory Pathogens in Asian and Pacific Rim Countries
  501. 2000 ECCMID: Gemifloxacin Demonstrates Potent In Vitro Activity Against Global Isolates of Antibiotic-resistant Streptococcus pneumoniae
  502. 2000 ASM: In Vitro Activity of Gemifloxacin Against Enterobacteriaceae Isolated in North America
  503. 2000 ASM: Activity of Gemifloxacin (SB-265805) Against Penicillin-, Macrolide- and Ciprofloxacin-resistant Streptococcus pneumoniae Isolated in the United States, Canada and Europe
  504. 2000 ASM: A Global Comparative In Vitro Surveillance Study of Gemifloxacin Against 24,955 Isolates in Europe, Canada and the United States